Stability
Predictability Across Development and Commercialization
Clinical Trial Execution Efficiency
High quality of medical services
With 13.0 hospital beds per 1,000 people, Japan ranks first in the world for hospital bed availability. Combined with universal medical standards and highly trained clinical teams, this contributes to outstanding medical care and high-integrity data collection.
One of the best clinical trial environments in the world
In IQVIA Institute's global trial prioritization index, Japan ranked 3rd in the world overall, excelling in operational infrastructure, clinical readiness, and patient availability.
Improved clinical trial environment: faster participant enrollment
Participant enrollment rates in Japan have substantially accelerated, backed by experienced Site Management Organizations (SMOs) and patient-centric site networks.
Study Duration and Investment Profile
Clinical trial duration and costs: Relatively short clinical trial duration
A research paper published by the Japan Pharmaceutical Manufacturers Association (JPMA) summarizes development timelines and investment profiles across Japan.
Drug Research and Development Timelines
In Japan, median development timelines are 20 months for Phase Ⅰ, 29 months for Phase Ⅱ, 31 months for Phase Ⅲ, and 10 months for regulatory review. Japan offers exceptionally predictable study spans.
Research and Development Costs for Pharmaceuticals
Median R&D costs in Japan are JPY 381M (Preclinical), JPY 859M (Phase Ⅰ), JPY 1,732M (Phase Ⅱ), JPY 4,183M (Phase Ⅲ), and JPY 154M for submission.
Contact Us
Speak with CMIC to plan and execute your Japan clinical trials with confidence.